Published in Vaccine Weekly, April 27th, 1998
The protection was the first demonstration that local administration of an artificial peptide-based vaccine elicited long-lasting, HIV specific local mucosal and systemic cytotoxic T-lymphocyte (CTL) responses.
"We can't be sure that the protection was due to lytic activity," said Jay Berzofsky of the National Cancer Institute, Bethesda, Maryland. "But there is clear evidence that one can get protection against mucosal challenge by stimulating CD8+ cells locally."
Berzofsky spoke in a presentation to the 1998...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.